The ScorranoLab

This is your reminder there is only ✨2 WEEKS✨to go until our final registration deadline for #FusionAging25 📜Final Few Poster Slots Remaining! 🗓️Deadline: Thursday 07 Aug 2025 🔗Register here: bit.ly/4lL9Y64

This work identifies OPA1-targeting strategies as promising for metastatic TNBC. Big thanks to the funders @AIRC_it @Fondaz_Veronesi 6/6 LS

Pharmacological inhibition with our OPA1 inhibitors MYLS22 and Opitor‑0 confirms selective vulnerability: these small molecules reduce migration and induce cell death exclusively in metastatic lines. 5/6

Kudos to Antigoni Diokmetzidou, @aurora_maracani, @mau_carr, @AnnaPellattiero, Erwan Rivière for their new @cddpress paper where we make good use of the Opa1 inhibitors that we generated in the lab! Check the paper out here rdcu.be/ew6LX 1/6

I promise that the style of our presentations is a little bit more plain. LS

This poster is a must have for labs working on #MCS! A guide through the work of so many outstanding labs (apologies if we did not cite your work). Hang it in your office or lab, it will please your eyes and inspire your mind! Kudos to the driving force Antigoni Diokmetzidou! -LS

11/11 Special thanks to @AIRC_it that funded this project @FRBiomedica since its inception and to grants from @FondazioneHeal @fondcariparo @mur_gov_. Many improved Opitors to follow, hoping to bring them soon to the clinics for the benefit of #AML and other cancer patients! LS

10/ Stay tuned for our collaborative work with the labs of @glytsou @iannisaifantis1 where we show how effective these new Opitors are in models of #AML, where #Venetoclax resistance can be driven by OPA1 and is an important and unmet clinical need!

Kudos to @AnnaPellattiero C Quirin @MagrinFederico, great collaborators S Moro A Mattarei @msturlese @ProfGavathiotis for our latest @ScienceAdvances paper science.org/doi/10.1126/sc…. Many years in the making but finally we have OPA1 inhibitors reverting cancer chemoresistance! 1/